LIVE ATTENUATED INFLUENZA VACCINE COMPOSITION AND PROCESS FOR PREPARATION THEREOF

The present disclosure provides compositions and methods for manufacturing and obtaining a live attenuated Influenza vaccine (LAIV) composition that can be delivered intranasally to provide protection against influenza virus infection. Said LAIV strains are based on cold adapted, temperature sensiti...

Full description

Saved in:
Bibliographic Details
Main Authors ANASPURE YASHODHAN DILIP, TUPE SHAM RAMDAS, GANGULY MILAN SHOMENATH, SAGAR UMESH GORAKH, DHERE RAJEEV MHALASAKANT, YEOLEKAR LEENA RAVINDRA, NARALE SWAPNIL PRABHAKAR, TYAGI PARIKSHIT DHARAMPAL
Format Patent
LanguageChinese
English
Published 12.11.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present disclosure provides compositions and methods for manufacturing and obtaining a live attenuated Influenza vaccine (LAIV) composition that can be delivered intranasally to provide protection against influenza virus infection. Said LAIV strains are based on cold adapted, temperature sensitive and attenuated phenotypes of master donor viruses (MDVs) containing the surface glycoprotein genes of the wild type pandemic or seasonal influenza strains. Also, said LAIV strains are further adapted to grow in MDCK cells (Madin Darby canine kidney cells). The use of eggs is avoided in large scale vaccine manufacturing. The purification process is devoid of chromatography steps. The said LAIV composition includes one or more live attenuated influenza vaccine virus and is devoid of polymers and surfactants. 本公开提供了用于制造和获得可鼻内递送以提供针对流感病毒感染的保护的减毒活流感疫苗(LAIV)组合物的组合物和方法。所述LAIV毒株基于包含野生型大流行性或季节性流感毒株的表面糖蛋白基因的主供体病毒(MDV)的冷适应、温度敏感和减毒表型。而且,所述LAIV毒株进一步适于在MDCK细胞(马丁达比狗肾细胞)中生长。在大规模疫苗生产中避免使用蛋。纯化过程没有色谱步骤。所述LAIV组合物包括一种或多种减毒活流感疫苗病毒,并且
Bibliography:Application Number: CN202080024926